SCHEMBL8407528

SCHEMBL8407528

CCCN(C(=O)C(C)(C)Br)c1ccc([N+](=O)[O-])c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 8/20 0.47
CYP3A4 P08684 3/20 0.46
PGR P06401 1/20 0.46
TSHR P16473 2/20 0.43
MAPK1 P28482 2/20 0.43
CES2 O00748 1/20 0.43
ABCB11 O95342 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
GLA P06280 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CHRM1 P11229 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
TBXA2R P21731 1/20 0.43
AADAC P22760 1/20 0.43
CYP2C19 P33261 1/20 0.43
ADRA1A P35348 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8409225 0.93 AR (0.45) ARCYP3A4PGRTSHRMAPK1
SCHEMBL8410301 0.91 AR (0.48) ARCYP3A4PGRTSHRMAPK1
SCHEMBL8407379 0.82 AR (0.50) ARCYP3A4PGRTSHRMAPK1
SCHEMBL11314718 0.78 AR (0.54) ARCYP3A4PGRTSHRMAPK1
SCHEMBL3047176 0.76 CYP3A4 (0.56) ARCYP3A4PGRTSHRMAPK1
SCHEMBL10395766 0.76 AR (0.50) ARCYP3A4PGRTSHRMAPK1
SCHEMBL11872742 0.74 TSHR (0.48) ARCYP3A4PGRTSHRMAPK1
SCHEMBL8407240 0.74 AR (0.56) ARCYP3A4PGRTSHRMAPK1
SCHEMBL3054200 0.74 CYP3A4 (0.61) ARCYP3A4PGRTSHRMAPK1
SCHEMBL15969823 0.74 AR (0.47) ARCYP3A4PGRTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5994362-A ADMINISTERING FINASTERIDE AND CASODEX MERCK & CO., INC. (US) 1999-11-30 US disclosed
EP-0514056-A2 Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry MERCK & CO. INC. (US) 1992-11-19 EP disclosed
WO-1992016233-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed